Prelude Therapeutics

Prelude Therapeutics Highlights Groundbreaking Blood Cancer Research at ASH 2025

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the publication of two abstracts featuring preclinical data from its JAK2V617F mutant-selective inhibitor program and CALR-targeted degrader antibody conjugates (DACs) discovery …

Prelude Therapeutics Highlights Groundbreaking Blood Cancer Research at ASH 2025 Read More